Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Astex Pharmaceuticals, Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Takeda Oncology.

Personalizing Care for Patients With Low- to High-Risk MDS: Applying the Science to Real-World Case Scenarios

Release Date: October 22, 2021
Expiration Date: October 22, 2022

Activity Overview

This online, on-demand virtual symposium focuses on the practical aspects of personalizing the management of patients with low- to high-risk myelodysplastic syndrome (MDS). The program includes a review of morphological diagnosis criteria and case presentations by expert faculty, who discuss targeted therapeutic options for MDS.

This educational activity is an archive of the live webcast held on September 9, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astex Pharmaceuticals, Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Takeda Oncology.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with MDS. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MDS are also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review available tools for MDS classification and risk stratification based on morphological, clinical, and cytogenetic criteria
  • Assess strategies to individualize therapy in MDS based on risk stratification and patient comorbidities
  • Summarize updated results from pivotal trials on evolving approaches for the treatment of low-, intermediate-, and high-risk MDS
  • Apply recent clinical data and updated guidelines to real-world cases of patients with lower- and higher-risk MDS

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
 

Chair

Anita Clayton, MD
Guillermo Garcia-Manero, MD
Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: Grant/Research Support: Bristol Myers Squibb; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; AbbVie Inc; Genentech, Inc; APR Applied Pharma Research sa; Curis, Inc; Gilead Sciences.


Faculty

Linda L. Carpenter, MD
Kelly S. Chien, MD
Assistant Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
 

Disclosures: Kelly S. Chien, MD, has no relevant financial relationships with ineligible companies.
 

Rami
Rami S. Komrokji, MD
Professor of Oncologic Sciences
University of South Florida
Senior Member
Section Head, - Leukemia & MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
 

Disclosures: Consultant: Abbvie Inc, Agios Pharmaceuticals Inc, Bristol Myers Squibb/Celgene, Geron, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation; Speakers’ Bureau: Abbvie Inc, Agios Pharmaceuticals Inc, Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
 


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By